-
AstraZeneca AB v. Mylan Pharmaceuticals Inc. DC CAFC
- 1:14-cv-00696
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 06/02/2014
- Closed: 02/02/2017
- Latest Docket Entry: 02/02/2017
- PACER
- Docket updated daily
1
Plaintiff
1
Defendant
1
Accused
Product
3
Patents-in-Suit
977
Days in
Litigation
-
AstraZeneca AB v. Mylan Pharmaceuticals Inc. DC CAFC
- 1:14-cv-00696
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 06/02/2014
- Closed: 02/02/2017
- Latest Docket Entry: 02/02/2017
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 25 |
<?insert-start id="REI-00018" date="20130430" ?>25. A compound that is <chemistry id="CHEM-US-00225" num="00225"><img id="EMI-C00225" he="29.04mm" wi="29.13mm" file="USRE044186-20130430-C00225.TIF" alt="embedded image" img-content="chem"
view more
|
Valid (103)
Entry 11 |
| 26 |
<?insert-start id="REI-00019" date="20130430" ?>26. The compound as defined in claim 25, wherein the pharmaceutically acceptable salt is the hydrochloride salt.<?insert-end id="REI-00019" ?>
|
Valid (103)
Entry 11 |
